This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:4C-D
From PsychonautWiki Archive
Revision as of 01:38, 26 July 2020 by >Dextromethorphan(started 4c-d, will complete later)
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
4-Methyl-2,5-dimethoxy-alpha-ethylphenethylamine (also known as ARIADNE, dimoxamineBL-3912 and more commonly as 4C-D) is a synthetic psychedelic that produces a mixture of psychedelic, entactogenic and stimulant effects when administered.
4C-D was first synthesized by Alexander Shulgin and documented in his 1991 book PiHKAL ("Phenethylamines I Have Known and Loved"). Shulgin has researched dosages up to 32 milligrams although anecdotal reports suggest that the dosage for 4C-D is generally higher than what Shulgin documented. Shulgin describes 4C-D as not a true psychedelic and it possessing anti-depressant effects. It has been researched as a potential therapeutic agent due to its mood-lifting effects
4C-D has been scarcely distributed as a gray area research chemical by online vendors. Many anecdotal reports suggest that the psychedelic effects begin to unfold at the higher dose range. The dosage levels of 4C-D are therefore not fully clear and one should start at a lower dose when researching this compound. It is highly advised to use harm reduction practices if using this substance.
Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential nootropic, albeit with mixed results.[1]
Today, 2C-D is used both recreationally and as an entheogen. It is rarely sold on the streets and almost exclusively distributed as a gray area research chemical by online vendors.
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences,[2], but initial trials by Alexander Shulgin at sub-threshold doses were carried out in 1964. Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978.[3] The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of DOM.
Shulgin notably referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without overly coloring the experience, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with.[citation needed] While some use this as evidence that 2C-D is relatively uninteresting as a psychedelic on its own, others strongly disagree with this assessment and hold that 2C-D is an unusually versatile and fully-fledged psychedelic in its own right.
Despite showing promise as a very functional psychostimulant[4][5] with successful studies investigating the use in psychotherapy in Germany,[6] 2C-D has not found widespread use. This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines.[7] Of these, it tends to be substantially harder to find and notably more expensive by weight.[citation needed]
Chemistry
Generic structure of a phenethylamine molecule
2C-D, or 2,5-dimethoxy-4-methylphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. 2C-D contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4 of the phenyl ring.
2C-D belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.
2C-D's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Subjective effects
The head space of 2C-D is described by many as being lucid, insightful and relatively normal in its thought processes even at moderate to high doses. The feeling of unaltered consciousness may be unsatisfying to users who want an intense experience because the head space is fairly normal, stable and therefore sometimes uninteresting to those who are new to hallucinogenic experiences.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Stimulation - In terms of its effects on the physical energy levels of the user, the 2C-D experience begins with mild sedation that gives way to moderate stimulation as the experience progresses. It lacks the forceful energetic push associated with most psychedelic phenethylamines.
Spontaneous physical sensations - The "body high" of 2C-D can be described as a pleasurable, all-encompassing comfort sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
Bodily control enhancement - Whilst at lower doses one may find that their bodily control is enhanced, at higher dosages it seems to become suppressed.
Nausea - In comparison to other phenethylamines such as 2C-E, 2C-I or 2C-B, any nausea produced by this substance tends to be very mild and dissipates quickly even with higher dosages.
Compared to other members of the 2C-x family like 2C-B, the visual effects of 2C-D have been noted for being understated until heavier doses are reached. After this point, a full spectrum of hallucinatory visual phenomena begin to appear.
Drifting(melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as low in detail, slow and smooth in motion, static in appearance and realistic in style.
The visual geometry of 2C-D be described as more similar in appearance to that of DOM or 25D-NBOMe than that of LSD, 2C-B or 2C-I. It can be comprehensively described as structured in its organization, organic in style, intricate in complexity, large in style, slow and smooth in motion, colorful in scheme, bright in color, blurred in its edges and equally rounded and angular in its corners. It gives off a natural feel at higher dosages. While the final level of 2C-D geometry has yet to be formally confirmed, it seems more likely that it would result in states of level 8B visual geometry over level 8A.
Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - In comparison to other psychedelics such as LSD, 2C-D is low in hallucinations embedded within visual geometry. However, when it does occur this particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, and interactive in style.
External hallucination (settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - 2C-D is capable of external hallucinations embedded within visual geometry. This particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They can be described as external in their manifestation, lucid in believability, and fixed in style.
Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
The toxicity and long-term health effects of recreational 2C-D use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 2C-D is a research chemical with very little history of human usage.
Anecdotal evidence from those within the community who have tried 2C-D suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
2C-D is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 2C-D is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-D presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 2C-D all psychedelics will have a reduced effect.
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
[[Wikipedia:Lithium_(medication)|DangerousInteraction::Lithium]] - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
]] - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 4C-D. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
]] - Tramadol is well-documented to lower the seizure threshold[8] and psychedelics may act to trigger seizures in susceptible individuals.[citation needed]
Legal status
Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.[9]
Austria: 2C-D is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[10]
Canada: 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[11]
China: 2C-D is a controlled substance in China as of October 2015.[12]
Denmark: 2C-D is added to the list of Schedule B controlled substances.[13]
Germany: 2C-D is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014.[14][15] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[16]
Japan: 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.[17]
Latvia: 2C-D is a Schedule I controlled substance.[18]
Sweden: 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.[19]
Switzerland: 2C-D is a controlled substance specifically named under Verzeichnis E.[20]
United Kingdom: 2C-D is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[21]
United States: 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.[22]
↑Zuba, D., & Sekula, K. (2013). Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis, 5(8), 634–645. https://doi.org/10.1002/dta.1397
↑Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN1556-9039.
↑"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.CS1 maint: Unrecognized language (link)
↑Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
